Please login to the form below
Glenmark Pharmaceuticals
Want to know which agency did which ad? Search using one of the options below.
« Previous page
1
Next page »
Agency:
Hamell
Product:
Maloff Protect
Client:
Glenmark Pharmaceuticals
Therapy area:
Infections and Infestations
« Previous page
1
Next page »
COVID-19 Updates and Daily News
Featured jobs
-
Omnichannel Strategy Consultant
-
Competitive Salary
-
Senior Account Manager
-
Competitive salary offered
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Data shows patients treated with Biogen's MS therapies mount an effective antibody response to COVID-19 vaccination
- US demand for COVID-19 antibody treatments rising fast
- EU “still interested” in Valneva COVID vaccine despite UK snub
- FDA accepts Regeneron’s REGEN-COV for priority review for treatment of COVID-19
- Merck and Ridgeback request EUA from US FDA for COVID-19 drug molnupiravir
- AZ’s Imfinzi combination shows promise in liver cancer
- Gilead’s Trodelvy set for EU approval in breast cancer
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
- Breaking the silence: It’s time to talk about the menopause
- FDA accepts Regeneron’s REGEN-COV for priority review for treatment of COVID-19
- New data shows Roche's Enspryng significantly reduces neuromyelitis optica spectrum disorder relapses
- Novo Nordisk settles US insulin pricing dispute for $100m
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Results of AstraZeneca’s TACKLE phase 3 trial show antibody combination reduces risk of severe COVID-19 or death
- Avenir Global moves four UK agencies into new office space in London
- Tonix Pharmaceuticals to develop TNX-102 for long COVID syndrome
- Xarelto no better than aspirin in secondary stroke study
PMHub
JPA Health
JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...
